We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Transient Urinary Incontinence After Holmium Laser Enucleation of the Prostate (HoLEP)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01108367
Recruitment Status : Completed
First Posted : April 22, 2010
Last Update Posted : May 10, 2011
Sponsor:
Information provided by:
Seoul National University Hospital

Brief Summary:

In men, urinary incontinence (UI) is relatively uncommon, and usually associated with some forms of prostate surgery. Thus, one of the risks of surgery for benign prostate hyperplasia (BPH) is postoperative UI. The guidelines of the American Urological Association for BPH treatment indicate that UI (2~5%) is relevant complications after transurethral prostatectomy (TURP). Rassweiler et al., based on a review of publications stated that early UI may occur in up to 30-40% of patients after TURP. Rigatti et al. reported that early postoperative urgency UI occurred in 38.6% (TURP) and 44% (holmium laser enucleation of the prostate; HoLEP) of surgically treated patients at 1-month after the surgery. Recently, the follow-up data for patients treated with HoLEP showed that transient stress UI developed in up to 44% after HoLEP. Although this alternative surgical treatment such as HoLEP can be performed safely with minimal complications, patients often face debilitating UI during the postoperative period before any improvement in micturition parameters occurs. Although this symptom ameliorates within a relatively short time, it usually cause significant stress and anxiety to the patient as far as their durations is concerned. In addition to its economic cost, UI is a distressing condition that has major impacts on a patient's quality of life. Social withdrawal, isolation, and depression occur in some patients.

Because this problem is usually temporary, there has been little attempt at addressing the issue. Therefore, there has been no research devoted specifically to transient de novo UI associated with HoLEP.

1. The aim of the present study was following:

  1. to investigate the incidence of transient de novo UI after HoLEP for BPH
  2. determine the predictors of early postoperative transient de novo UI.

Condition or disease
Prostatic Hyperplasia Incontinence

Study Type : Observational
Actual Enrollment : 204 participants
Observational Model: Cohort
Time Perspective: Retrospective
Official Title: Predictor of Transient Urinary Incontinence Following Holmium Laser Enucleation of the Prostate
Study Start Date : November 2009
Primary Completion Date : March 2010

Resource links provided by the National Library of Medicine

U.S. FDA Resources





Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   50 Years and older   (Adult, Senior)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
men who underwent HoLEP for lower urinary tract symptoms (LUTS) with BPH refractory to alpha blocker medication
Criteria

Inclusion Criteria:

  • age older than 50 years
  • presence of moderate or severe LUTS (International Prostate Symptom Score [IPSS] greater than 8)or maximum flow rate of less than 10 mL/s

Exclusion Criteria:

  • previous prostate surgery
  • urethral stricture
  • prostate carcinoma
  • neurogenic bladder disease

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01108367


Sponsors and Collaborators
Seoul National University Hospital
Investigators
Principal Investigator: Min Chul Cho, M.D. Seoul National University Hospital
Study Chair: Jae-Seung Paick, M.D.,Ph.D. Seoul National University Hospital

Publications:
Responsible Party: Jae-Seung Paick/M.D.,Ph.D., Seoul National University Hospital
ClinicalTrials.gov Identifier: NCT01108367     History of Changes
Other Study ID Numbers: HoLEPUI
First Posted: April 22, 2010    Key Record Dates
Last Update Posted: May 10, 2011
Last Verified: May 2011

Additional relevant MeSH terms:
Urinary Incontinence
Enuresis
Hyperplasia
Prostatic Hyperplasia
Urination Disorders
Urologic Diseases
Lower Urinary Tract Symptoms
Urological Manifestations
Signs and Symptoms
Behavioral Symptoms
Elimination Disorders
Mental Disorders
Pathologic Processes
Prostatic Diseases
Genital Diseases, Male